

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
15 February 2001 (15.02.2001)

PCT

(10) International Publication Number
WO 01/10443 A1

(51) International Patent Classification⁷: **A61K 31/4745**,
9/52, 47/38

(21) International Application Number: **PCT/EP00/06590**

(22) International Filing Date: **11 July 2000 (11.07.2000)**

(25) Filing Language: **English**

(26) Publication Language: **English**

(30) Priority Data:
9918885.6 **10 August 1999 (10.08.1999)** **GB**

(71) Applicant (for all designated States except US): **PHARMACIA & UPJOHN S.P.A. [IT/IT]; Via Robert Koch, 1.2, I-20152 Milano (IT).**

(72) Inventors; and

(75) Inventors/Applicants (for US only): **CIVAROLI, Paola [IT/IT]; Via Giuseppe Frua, 20, I-20100 Milano (IT). MUGGETTI, Lorena [IT/IT]; Via Trento, 38, I-20035 Meda (IT). MARTINI, Alessandro [IT/IT]; Via Desiderio da Settignano, 14, I-20100 Milano (IT).**

(81) Designated States (national): **AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.**

(84) Designated States (regional): **ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).**

Published:

- *With international search report.*
- *Before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments.*

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.



WO 01/10443 A1

(54) Title: **PHARMACEUTICAL FORMULATIONS IN HYDROXYPROPYLMETHYLCELLULOSE CAPSULES**

(57) Abstract: **An oral pharmaceutical formulation which comprises, in a hydroxypropylmethylcellulose capsule, a camptothecin analogue dispersed or solubilised in a semi-solid matrix. These formulations are useful for the treatment of neoplastic diseases.**

PHARMACEUTICAL FORMULATIONS IN HYDROXYPROPYLMETHYLCELLULOSE CAPSULES

5

FIELD OF THE INVENTION

The present invention relates to oral dosage forms for camptothecin (CPT) analogues, such as, for example, (S)-[1,4'-Bipiperidine]-1'-carboxylic acid, 4,11-Diethyl-3,4,12,14-tetradhydro-4-hydroxy-3,14-dioxo-1H-pyrano [3',4':6,7]indolizino [1,2-b] quinolin-9-yl ester, monohydrochloride, trihydrate also known as irinotecan hydrochloride trihydrate or CPT-11, in hydroxypropylmethylcellulose capsules.

15 BACKGROUND OF THE INVENTION

CPT-11 is a water-soluble pro-drug of SN-38 (7-ethyl-10-hydroxy-CPT), a biologically potent derivative of the anticancer agent CPT, a topoisomerase I inhibitor. CPT-11 was proven efficacious in a variety of malignancies. Its clinical efficacy has been highlighted by the fact that CPT-11 is the first new active drug to obtain marketing approval in forty years for colorectal cancer.

The intravenous drug form of CPT-11 is currently used for the treatment of colorectal cancer.

25 It is well known that parenteral administration of antitumor drugs is associated with some intrinsic disadvantages and drawbacks, e.g., patient discomfort or the requirement for the patient to travel to the physician's office for drug administration, with obvious results in patient inconvenience.

30 Thus the need has arisen to find oral formulations of antitumoral drugs that would allow longer dosing regimens, as with continuous infusion, but without the inconvenience or the discomfort of the patient.

Classic oral formulations are, for example, solid oral dosage forms, that are medication delivery systems presented as solid

dose units readily administered by mouth. The group includes tablets, capsules, cachets and pills, as well as bulk or unit-dose powders and granules. The group constitutes the most popular form of presentation, and tablets and capsules account for the
5 greatest number of preparations in this category.

It has long been known in the pharmaceutical industries that capsules are a convenient form for the oral administration of a variety of active agents because of their relative ease of manufacture (compared with other dosage forms such as tablets),
10 flexibility of size and dose. Capsules have traditionally been used for powder or granule formulations, but, in recent years, capsules have been adapted to contain the active ingredient in the form of paste, semi-solid or liquid formulation.

Since, for example, CPT-11 is classified as a class I cytotoxic
15 agent, any form of leakage from the dosage form would present a safety concern.

Therefore, formulations as tablets or powder-filled capsules are not as safe and user-friendly as semi-solid filled capsules, since the risks of leakage of the active ingredient from the unit
20 dosage form, both during manufacturing and distribution, is extremely high.

Thus, in light of the above-mentioned problem about the safe handling of CPT-11, it is desirable to formulate CPT-11 as a semi-solid dispersion or solution to be filled into capsules.

25 In particular, a thermoplastic hot-melt type capsule formulation would result in enhanced stability and minimization of leakage concerns.

Furthermore, it is known that the presence of certain active principles and/or of certain ingredients in the filling medium
30 can promote cross-linking in the capsule gelatin shell with the passage of time and/or under stressed conditions. When cross-linking occurs, the gelatin shell becomes less soluble in aqueous media. Cross-linking causes retardation of the disintegration of the capsule shell, and thus retardation of the dissolution of the
35 capsule contents, relative to identical capsules, which have not

been subjected to aging or storing at stressed conditions (i.e. temperature and humidity).

Thus, when a filled gelatin capsule contains an ingredient, which promotes cross-linking in the gelatin shell, such as, e.g. a polyethyleneglycol (PEG), it is challenging to prepare a formulation, which does not show retarded disintegration and/or dissolution when the formulation grows old.

There is therefore a need to prepare a safe and stable oral encapsulated formulation containing a CPT analogue which does not present neither leakage nor stability problems.

The present invention fulfills such a need by providing stable oral pharmaceutical formulations of CPT analogues which avoid chemical interaction between the active ingredient and/or the excipients with capsule shells and maintain the dissolution performances of the formulations with aging.

DESCRIPTION OF THE INVENTION

In one aspect of this invention there is provided an oral pharmaceutical formulation, which comprises a camptothecin analogue dispersed or solubilised in a semi-solid matrix, filled into a hydroxypropyl-methylcellulose (HPMC) capsule.

The camptothecin analogue of the present invention is selected from the group comprising: CPT-11, topotecan, SN-38, SN-22, 9-amino-20(S)-CPT and 9-nitro-20(S)-CPT.

In particular, the present invention provides an oral pharmaceutical formulation, which comprises CPT-11, dispersed or solubilized into a semi-solid matrix, filled into a hydroxypropylmethylcellulose capsule.

A suitable semi-solid matrix for the formulation according to this invention can be, e.g., a polyethyleneglycol (PEG) in the molecular weight range between 400 and 20000, preferably between 1000 and 4000 and specifically 3000, optionally in combination with suitable excipients for semi-solid matrix compositions.

Suitable excipients can be, for example, pharmaceutical or food-grade oils, e.g. soya or fractionated coconuts oils; surfactants,

e.g. polysorbates; poloxamers, i.e. polyoxyethylene-polyoxypropylene copolymers; solubilising agent, e.g. ethanol and triacetin; natural or synthetic glycerides, e.g. fractionated medium chain glycerides or saturated polyglycol glycerides; or phospholipids.

The formulations according to the invention may be prepared by means of conventional techniques well known to one of ordinary skill in the art.

Typically, the semi-solid matrix to be filled into capsules may be prepared by adding the camptothecin analogue to a molten homogeneous mixture of the excipients. This is then followed by thorough mixing of the molten mass and capsule filling using standard techniques. Hydroxypropylmethylcellulose capsules are chosen as primary packaging for such a formulation.

For example, the amount of CPT-11 may be in the range of from about 0.2 to about 200 mg, preferably from about 20 to about 100 mg per unit dose.

Generally, a semi-solid matrix formulation is a dispersion or a solution of the active ingredient in thermosoftening hot melt inert carrier prepared by mixing or homogenization.

The obtained semi-solid matrix is therefore filled into capsules as liquid using fluid-filling pumps and allowed to solidify at ambient temperature. The major advantage of semi-solid formulations is the safety during manufacturing, being the drug dispersed or dissolved in a liquid mass. At ambient condition such a formulation is solid, providing better chemical stability and minimizing leakage problems.

Selection of suitable excipients for semi-solid matrix formulations is commonly based on physico-chemical, rheological and thermal properties, compatibility with drug and capsule shell as well as on the required drug release profile and bioavailability characteristics of the final dosage form.

In general, thermosoftening materials should have a melting temperature in the range of about 30°C to 70°C and a quite rapid solidification time at ambient condition to avoid any leakage

phenomena from capsule after filling and/or during the sealing operation.

Drugs or excipients containing aldehyde groups, or producing aldehyde in decomposition, promote cross-linking in conventional capsules shells made from gelatin, forming a thin insoluble membrane that may delay dissolution.

Moreover, in semi-solid matrix formulations any interaction between the components and the capsule shell is magnified in comparison to powder filled capsules, being the surface contact area between the active ingredients/excipients and the gelatin shell higher.

It can be considered as an unexpected result the fact that the formulations of the present invention are able to guarantee the maintenance of the physico-chemical characteristics of the formulations during manufacturing and storage and to overcome the undesired cross-linking effect, that is practically highlighted by a reduced drug release profile from the dosage forms, especially with aging.

Dissolution rate test results, recovered during accelerated stability studies, as reported in the Examples 1 to 5, clearly demonstrate the increased stability shown by CPT-11 formulations placed into hydroxypropylmethylcellulose capsules according to the invention, when compared with the same CPT-11 formulations placed into conventional hard gelatin capsules.

The following examples are given with the purpose to better illustrate the invention but in no way they must be considered as a limitation of the scope of the invention itself.

It is to be understood that, although the examples reported in the description consider the use of CPT-11 as a representative compound of the camptothecin analogue compounds, the formulation approach according to the invention may be analogously applicable to other camptothecin analogues.

EXAMPLE 1

In the following table 1, the dissolution rate test results, recovered during an accelerated stability study, on Batch ND1216

(CPT-11 semi-solid matrix formulation in PEG1000 - 100 mg CPT-11/capsule - Hard Gelatin Capsule as primary packaging) are shown.

The results are expressed as percent labeled amount (Release %) and its relative standard deviation percent (r.s.d. %) of the active dissolved after 60 minutes in simulated gastric fluid (SGF) without pepsin.

table 1

Storage (Time/conditions)	Release (%)	r.s.d. (%)	Dissolution medium
Initial	100.2	0.3	SGF without pepsin
1 month / 55°C	57.0	64.0	SGF without pepsin
1 month / 40°C+75%R.H.	74.6	20.3	SGF without pepsin

R.H. = Relative Humidity

As evident from the above—tabulated data, the release performances of the active from hard gelatin capsules decrease with aging. No chemical degradation of the active, that could justify such a reduction in the dissolution release performances, was observed.

EXAMPLE 2

In the following table 2, the dissolution rate test results, recovered during an accelerated stability study, on Batch D54G01 (CPT-11 semi-solid matrix formulation in PEG1000 - 50 mg CPT-11/capsule - Hard Gelatin Capsule as primary packaging) are shown.

The results are expressed as percent labeled amount (Release %) and its relative standard deviation percent (r.s.d. %) of the active dissolved after 60 minutes in simulated gastric fluid (SGF) without pepsin.

Table 2

Storage (Time/conditions)	Release (%)	r.s.d. (%)	Dissolution medium
Initial	100.1	0.4	SGF without pepsin
1 month / 40°C+75%R.H.	56.0	67.4	SGF without pepsin
1 month / 40°C+75%R.H.	97.5 (1)	2.2	SGF without pepsin

R.H. = Relative Humidity

5 (1) Dissolution performed on 'capsule content'

As evident from the above-tabulated data, the release performances of the active from hard gelatin capsules decrease with aging. No chemical degradation of the active, that could
10 justify such reduction in the dissolution release performances, was observed.

The good dissolution performance of the formulation stored for 1 month at 40°C 75% R.H., by removing the content from the gelatin shell before the dissolution testing, is the clear
15 demonstration that the reduction in the release profile is exclusively due to the partial insolubilization of the capsule shell induced by the cross-linking process.

20 EXAMPLE 3

In the following table 3, the dissolution rate test results, recovered during an accelerated stability study on Batch ND1283 (CPT-11 semi-solid matrix formulation in PEG3000 - 100 mg CPT-11/capsule - Hard Gelatin Capsule as primary packaging) are
25 shown.

The results are expressed as percent labeled amount (Release %) and as minimum and maximum release percent value of the active dissolved after 60 minutes in simulated gastric fluid (SGF) with and without pepsin.

The use of pepsin is allowed by regulatory authorities in order to overcome the cross-linking issue of hard gelatin capsules. In fact, if the cross-linked gelatin is disrupted by the mechanical forces of gastric emptying or is broken down by digestive enzymes, its formation would not affect absorption and bioavailability of the active. The United States Food and Drug Administration (FDA) / Industry Gelatin Capsule Working Group concluded that formation of an insoluble membrane could be considered to have a negligible impact on drug bioavailability if the capsules dissolved during the 'two-tiered dissolution test' which employs a methods containing digestive enzymes.

Table 3

Storage (Time/conditions)	Release (%)	Minimum and maximum release (%) value	Dissolution medium
Initial	92.1	87.9 - 97.4	SGF without pepsin
1 month / 55°C	9.8	5.2 - 16.8	SGF without pepsin
1 month / 40°C+75%R.H.	6.3	3.7 - 11.5	SGF without pepsin
1 month / 55°C	89.6	91.2 - 97.4	SGF with pepsin
1 month / 40°C+75%R.H.	91.9	89.2 - 96.1	SGF with pepsin
3 month / 40°C+75%R.H.	69.6	37.6 - 89.9	SGF with pepsin

R.H. = Relative Humidity

It is clearly evident from the above-tabulated data that the addition of pepsin to the dissolution medium is not sufficient to overcome the problem. After 3 month storage at 40°C and 75%R.H., not even the addition of pepsin to the dissolution medium has allowed obtaining a complete release of the active from the formulation. No chemical degradation of the active, that could justify such reduction in the dissolution release performances, was observed.

EXAMPLE 4

In the following table 4, the dissolution rate test results, recovered during an accelerated stability study, on Batch ND1651 (CPT-11 semi-solid matrix formulation in PEG3000 - 50 mg CPT-11/capsule - Hydroxypropylmethylcellulose Capsule as primary packaging) are shown.

The results are expressed as percent labeled amount (Release %) and its relative standard deviation percent (r.s.d. %) of the active dissolved after 60 minutes in simulated gastric fluid (SGF) without pepsin.

Table 4

Storage (Time/conditions)	Release (%)	r.s.d. (%)	Dissolution medium
Initial	101.5	2.5	SGF without pepsin
1 month / 55°C	100.2	10.5	SGF without pepsin
3 month / 40°+75%R.H.	106.5	1.9	SGF without pepsin

It is clearly evident from the above-tabulated data that there is not any influence of aging on the release performances of the active from the HPMC formulation. The same unit dosage strength (i.e. 50 mg CPT-11/capsule), packed into hard gelatin capsule, showed reduced dissolution behavior already after 1 month storage at 40°C + 75% R.H. (as above shown in Example 2), while a 3 month storage at the same condition has no effect at all on the dissolution performance of the formulation manufactured into hydroxypropylmethylcellulose capsule. No chemical degradation of the active was observed.

EXAMPLE 5

In the following table 5, the dissolution rate test results, recovered during an accelerated stability study, on Batch ND1655 (CPT-11 semi-solid matrix formulation in PEG3000 - 100 mg CPT-

11/capsule - Hydroxypropylmethylcellulose Capsule as primary packaging) are shown.

The results are expressed as percent labeled amount (Release %) and its relative standard deviation percent (r.s.d. %) of the active dissolved after 60 minutes in simulated gastric fluid (SGF) without pepsin.

Table 5

Storage (Time/conditions)	Release (%)	r.s.d. (%)	Dissolution medium
Initial	90.3	4.1	SGF without pepsin
1 month / 55°C	90.2	1.6	SGF without pepsin
1 month / 40°C+75%R.H.	94.6	2.0	SGF without pepsin
3 month / 40°+75%R.H.	92.3	2.0	SGF without pepsin

It is clearly evident from the above-tabulated data that there is not any influence of aging on the release performances of the active from the HPMC encapsulated formulation. The same unit dosage strength (i.e. 100 mg CPT-11/capsule), packed into hard gelatin capsule, showed reduced dissolution behavior already after 1 month storage at 40°C + 75% R.H. (as above shown in Example 3), while a 3 month storage at the same condition has no effect at all on the dissolution performance of the formulation manufactured into hydroxypropylmethylcellulose capsule. No chemical degradation of the active was observed.

EXAMPLE 6

In this example, typical semi-solid filling matrices, suitable for hydroxypropylmethylcellulose capsules, are shown. The below mentioned formulae are not intended to be exhaustive or to limit anyway the scope of the invention itself.

11

FORMULA A	<u>mg per capsule</u>	<u>mg per capsule</u>
CPT-11	50 mg	100 mg
Polyethylenglycol3000	575 mg	525 mg
Fill weight per capsule	625 mg	625 mg

5

Hydroxypropylmethylcellulose capsules size 0

FORMULA B	<u>mg per capsule</u>	<u>mg per capsule</u>
CPT-11	50 mg	100 mg
10 Polyethylenglycol1000	575 mg	525 mg
Fill weight per capsule	625 mg	625 mg

Hydroxypropylmethylcellulose capsules size 0

15 FORMULA C	<u>mg per capsule</u>	<u>mg per capsule</u>
CPT-11	50 mg	100 mg
Polyethylenglycol3000	520 mg	470 mg
Triacetin	50 mg	50 mg
Polysorbate80	5 mg	5 mg
20 Fill weight per capsule	625 mg	625 mg

Hydroxypropylmethylcellulose capsules size 0

FORMULA D	<u>mg per capsule</u>	<u>mg per capsule</u>
25 CPT-11	50 mg	100 mg
Polyethylenglycol3000	520 mg	470 mg
Polyethylenglycol400	50 mg	50 mg
Polysorbate80	5 mg	5 mg
Fill weight per capsule	625 mg	625 mg

30

Hydroxypropylmethylcellulose capsules size 0

FORMULA E	<u>mg per capsule</u>	<u>mg per capsule</u>
CPT-11	50 mg	100 mg
35 Polyethylenglycol3000	525 mg	475 mg
Gelucire44/14	50 mg	50 mg

Fill weight per capsule

625 mg

625 mg

Hydroxypropylmethylcellulose capsules size 0

- 5 Another aspect of the present invention provides a method for treating a tumor in a mammal, including a human, which comprises administering to said mammal an oral pharmaceutical formulation of a camptothecin analogue as described in the present invention.
- 10 The formulations according to the invention are useful for treating neoplastic diseases, reducing tumor burden, preventing or treating metastasis of neoplasms and preventing recurrences of tumor/neoplastic growths in mammals.
- In particular, formulations according to the present invention,
- 15 wherein the camptothecin analogue is CPT-11, are suitable for the treatment of colorectal cancer.

CLAIMS

1. An oral pharmaceutical formulation which comprises, in a hydroxypropylmethylcellulose capsule, a camptothecin analogue dispersed or solubilised in a semi-solid matrix.
5
2. A formulation according to claim 1, wherein the camptothecin analogue is selected from CPT-11, topotecan, SN-38, SN-22, 9-amino-20(S)-CPT and 9-nitro-20(S)-CPT.
10
3. A formulation according to claim 1 wherein the camptothecin analogue is CPT-11.
4. A formulation according to claim 3 which comprises from 0.2 to 200 mg per unit dose of CPT-11.
15
5. A formulation according to claim 4 which comprises from 20 to 100 mg per unit dose of CPT-11.
- 20 6. A formulation according to any one of the preceding claims wherein the semi-solid matrix is a polyethyleneglycol with a molecular weight of from 400 to 20000.
- 25 7. A formulation according to claim 6, wherein the polyethyleneglycol has a molecular weight of from 1000 to 4000.
8. A formulation according to claim 7 wherein the polyethyleneglycol has a molecular weight of 3000.
30
9. A formulation according to any one of the preceding claims which further comprises an excipient for the semi-solid matrix.
- 35 10. A formulation according to claim 9 wherein the excipient is selected from a food-grade oil, a surfactant, a poloxamer, a solubilising agent, a natural or synthetic glyceride and a phospholipid.

11. An oral pharmaceutical formulation as defined in claim 1 for use in a method of treatment of the human or animal body by therapy.
- 5 12. A formulation as claimed in claim 11 for use in the treatment of neoplastic diseases, the reduction of tumors, the prevention or treatment of neoplasm metastasis or the prevention of recurrences of tumor or neoplastic growths in mammals.
- 10 13. A formulation as defined in claim 3, for use in the treatment of colorectal cancer.

INTERNATIONAL SEARCH REPORT

International Application No:
PCT/EP 00/06590

A. CLASSIFICATION OF SUBJECT MATTER
A61K31/4745,A61K9/52,A61K47/38

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	WO 99/06031 A1 (SMITHKLINE BEECHAM CORP.) 11 February 1999, abstract, claims. --	1, 2, 9-12
Y	WO 98/05310 A1 (HISAMITSU PHARMACEUTICAL CO., INC.) 12 February 1998, abstract. --	1-2, 6, 9-13
Y	WO 95/29677 A1 (BIONUMERIK PHARMAVEUTICALS, INC.) 09 November 1995, page 7, lines 16-19, page 14, lines 1-6, claims 1,4,11,12. --	1, 2, 9-12
Y	US 5726181 A (HAUSHEER et al.) 10 March	1-3, 6, 9-

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents:

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

- "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- "&" document member of the same patent family

Date of the actual completion of the international search

04 October 2000

Date of mailing of the international search report

13. 12. 2000

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

KRENN

INTERNATIONAL SEARCH REPORT

International Application No.

PCT/EP 00/06590

C. (Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
	1998, abstract, column 1, lines 57-67, claims. -----	13

ANHANG

Zum internationalen Recherchenbericht über die internationale Patentanmeldung Nr.

In diesem Anhang sind die Mitglieder der Patentfamilien der im obengenannten internationalen Recherchenbericht angeführten Patentdokumente angegeben. Diese Angaben dienen nur zur Unterrichtung und erfolgen ohne Gewähr.

ANNEX

To the International Search Report to the international Patent Application No.

PCT/EP 00/06590 SAE 294432

This annex lists the patent family members relating to the patent documents cited in the above-mentioned search report. The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

ANNEXE

Au rapport de recherche international relatif à la demande de brevet international n°

La présente annexe indique les membres de la famille de brevets relatifs aux documents de brevets cités dans le rapport de recherche international visée ci-dessus. Les renseignements fournis sont donnés à titre indicatif et n'engagent pas la responsabilité de l' Office.

Im Recherchenbericht angeführte Patentdokumente Patent document cited in search report Document de brevet cité dans le rapport de recherche	Datum der Veröffentlichung Publication date Date de publication	Mitglied(er) der Patentfamilie Patent family member(s) Membre(s) de la famille de brevets	Datum der Veröffentlichung Publication date Date de publication
WO A1 9906031	11-02-1999	AU A1 86045/98 ZA A 8806877	22-02-1999 15-06-1999
WO A1 9805310	12-02-1998	CN A 1226822 EP A1 819228 JP A2 10152431	25-08-1999 02-06-1999 09-06-1998
WO A1 9529677	09-11-1995	CA AA 1188297 EP A1 758237 JP T2 8512280 US A 8597829 US A 8604233	09-11-1995 19-02-1997 09-12-1997 28-01-1997 18-02-1997
US A 5726181	10-03-1998	AU A1 82223/96 AU B2 894677 CA AA 1223259 CN A 1187126 EP A1 831825 JP T2 11506463 WO A1 8639143 US A 8880133 US A 8935967 US A 8959022 US A 8959023 US A 8900419 US A 8955467 US A 8958937	24-12-1996 23-07-1998 12-12-1996 08-07-1998 01-04-1998 08-06-1999 12-12-1996 09-03-1999 10-08-1999 12-01-1999 12-01-1999 04-05-1999 21-09-1999 28-09-1999